One-year direct costs of biological therapy in rheumatoid arthritis and its predictive factors: data from the Moroccan RBSMR registry
Authors:
- Safaa FellousSFSafaa Fellous
- Hanan RkainHRHanan Rkain
- Samir AhidSASamir Ahid
- Redouane AbouqalRARedouane Abouqal
- Latifa TahiriLTLatifa Tahiri
- Ihsane HmamouchiIHIhsane Hmamouchi
- Lahsen AchemlalLALahsen Achemlal
- Imane El BouchtiIBImane El Bouchti
- Abdellah El MaghraouiAMAbdellah El Maghraoui
- Imad GhozlaniIGImad Ghozlani
- Hasna HassikouHHHasna Hassikou
- Taoufik HarzyTHTaoufik Harzy
- 2 January 2021
- journal article
- research article
- Published by Springer Nature in Rheumatology International
- Vol. 41 (4) , 787-793
Abstract
The aim of the study was to estimate the annual direct costs of biological therapies in rheumatoid arthritis (RA), and to establish possible factors associated with those costs. The main data source was the Moroccan registry of biological therapies in rheumatic diseases (RBSMR Registry). We included patients with available 1-year data. Variables related to socio-economic status, disease and biological therapy were collected. Direct costs included prices of biologics, costs of infusions, and subcutaneous injections. Differences in costs across groups were tested by Mann–Whitney and Kruskal–Wallis tests. Correlations analysis was performed in search of factors associated with high costs. We included 197 rheumatoid arthritis patients. The mean age was 52.3 ± 11 years, with female predominance 86.8%. Receiving one of the following therapies: rituximab (n = 132), tocilizumab (n = 37), or TNF-blockers (n = 28). Median one-year direct costs per patient were €1665 [€1472–€9879]. The total annual direct costs were € 978,494. Rituximab, constituted 25.7% of the total annual budget. TNF-blockers and tocilizumab represented 27.3% and 47% of this overall budget, respectively. Although the costs were not significantly different in terms of gender or level of study, the insurance type significantly affected the cost estimation. A positive correlation was found between the annual direct cost and body mass index (r = 0.15, p = 0.04). In Morocco, a developing country, the annual direct costs of biological therapy are high. Our results may contribute to the development of strategies for better governance of these costs.Keywords
This publication has 28 references indexed in Scilit:
- A Clinical Update and Global Economic Burden of Rheumatoid ArthritisEndocrine, Metabolic & Immune Disorders - Drug Targets, 2018
- Advances in the Treatment of Rheumatoid ArthritisNorth Carolina Medical Journal, 2017
- An estimate of the cost of administering intravenous biological agents in Spanish day hospitalsTherapeutics and Clinical Risk Management, 2017
- Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims DataClinical Therapeutics, 2016
- Canadian Estimates of Health Care Utilization Costs for Rheumatoid Arthritis Patients With and Without Therapy With Biologic AgentsArthritis Care & Research, 2014
- Direct medical costs associated with rheumatoid arthritis in Turkey: analysis from National Claims DatabaseRheumatology International, 2013
- Profile and course of early rheumatoid arthritis in Morocco: a two-year follow-up studyBMC Musculoskeletal Disorders, 2011
- Fatigue and severity of rheumatoid arthritis in Moroccan patientsRheumatology International, 2011
- Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA StudyArthritis Research & Therapy, 2010
- Socioeconomic impact of rheumatoid arthritis in MoroccoJoint Bone Spine, 2006